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Purpose: To compare the 6-month efﬁcacy and safety proﬁle of an individualized stabilization criteriaedriven
pro re nata (PRN) regimen of ranibizumab 0.5 mg with or without laser versus laser alone in patients with visual
impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).
Design: A 24-month, prospective, open-label, randomized, active-controlled, multicenter, phase IIIb study.
Participants: A total of 455 patients.
Methods: Eligible patients were randomized 2:2:1 to receive ranibizumab (n ¼ 183), ranibizumab with laser
(n ¼ 180), or laser only (n ¼ 92). Patients treated with ranibizumab with or without laser received a minimum of 3
initial monthly ranibizumab injections until visual acuity (VA) stabilization, and VA-based PRN dosing thereafter. In
the ranibizumab with laser and laser-only groups, laser was given at the investigator’s discretion at a minimum
interval of 4 months and if VA was <79 letters.
Main Outcome Measures: Mean change from baseline at month 6 in best-corrected visual acuity (BCVA)
(primary end point) and central subﬁeld thickness, and safety over 6 months. Exploratory objectives were to
evaluate the inﬂuence of baseline BCVA, disease duration, and ischemia on BCVA outcomes at month 6.
Results: Baseline mean BCVA was 57.7 letters, and mean BRVO duration was 9.9 months. Ranibizumab with
or without laser was superior to laser only in improving mean BCVA from baseline at month 6 (14.8 and 14.8 vs.
6.0 letters; both P < 0.0001; primary end point met). Patients with a shorter BRVO duration at baseline had a
higher mean BCVA gain than those with a longer BRVO duration. Patients with a poor baseline VA had a better
BCVA gain than those with a higher baseline VA, although ﬁnal BCVA was lower in those with poor baseline VA. In
the ranibizumab with or without laser groups, the presence of some macular ischemia at baseline did not inﬂu-
ence mean BCVA gains. There were no new ocular or nonocular safety events.
Conclusions: Ranibizumab with an individualized VA-based regimen, with or without laser, showed statis-
tically signiﬁcant superior improvement in BCVA compared with laser alone in patients with BRVO. Overall, there
were no new safety events other than those reported in previous studies. Ophthalmology 2016;123:1332-
1344 ª 2016 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.Antievascular endothelial growth factor (VEGF) treatment is
the current standard of care for macular edema secondary to
branch retinal vein occlusion (BRVO).1 Ranibizumab 0.5 mg
was approved by the US Food and Drug Administration in
June 2010 and by the European Union in 2011 for the
treatment of visual impairment due to macular edema
secondary to BRVO, based on the 6-month results of a
phase III, randomized, double-masked, controlled study, the
BRAnch Retinal Vein Occlusion: Evaluation of Efﬁcacy and
Safety (BRAVO) trial, using a ﬁxed monthly injection
regimen in the ﬁrst 6 months.21332  2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier IncThe BRIGHTER study (group members of this study are
cited in Appendix 1, available at www.aaojournal.org) was a
phase IIIb, multicenter study assessing the efﬁcacy and
safety proﬁle of an individualized stabilization
criteriaedriven pro re nata (PRN) dosing regimen of ranibi-
zumab 0.5 mg alone or in combination with laser versus laser
photocoagulation in patients with visual impairment due to
macular edema secondary to BRVO.
This study is being conducted to show that the stabiliza-
tion criteriaedriven PRN dosing regimen of ranibizumab 0.5
mg, as approved in the European Union,3 with or without.
http://dx.doi.org/10.1016/j.ophtha.2016.02.030
ISSN 0161-6420/16
Tadayoni et al  Ranibizumab versus Laser in BRVOadjunctive laser has efﬁcacy similar to the monthly dosing
regimen that was assessed in the BRAVO study.2
The BRAVO study was the ﬁrst prospective 12-month,
randomized, sham-controlled, multicenter study that demon-
strated the effectiveness of ranibizumab in managing patients
with macular edema secondary to BRVO. The improvements
in best-corrected visual acuity (BCVA) and central foveal
thickness (CFT) observed with a monthly dosing of ranibi-
zumab 0.5 mg in the ﬁrst 6 months (baseline to month 5; at
month 6, mean change in BCVA: þ18.3 letters [primary end
point] and mean change in CFT: 345.2 mm)2 were largely
maintained with a PRN dosing regimen and monthly
monitoring until month 12 (mean change in BCVA: þ18.3
letters and mean change in CFT: 347.4 mm).4
The HORIZON study (cohort 2; ClinicalTrials.gov
identiﬁer: NCT00379795) was a 1-year, open-label exten-
sion of the BRAVO and Ranibizumab for the Treatment of
Macular Edema after Central Retinal Vein OcclUslon
Study: Evaluation of Efﬁcacy and Safety (CRUISE) studies.
In this study, it was observed that the gains in BCVA
achieved at the end of 12 months in the BRAVO and
CRUISE studies were maintained for an additional 12
months with a PRN dosing regimen and with less frequent
monitoring. A total of 60.3% of patients gained 15 letters
in the HORIZON study (similar to 60.3% at month 12 in the
BRAVO study).5,6
The BRIGHTER study is designed to address the
following questions to aid physicians in optimizing treat-
ment for patients with BRVO: (1) provide long-term data on
the efﬁcacy and safety of the individualized visual acuity
(VA) stabilization criteriaedriven PRN dosing regimen of
ranibizumab 0.5 mg in a broad patient population with
BRVO, including those with macular ischemia; and (2) the
impact of adjunct laser treatment on BCVA outcome and the
number of ranibizumab injections required. Here, we report
the 6-month primary and main secondary outcomes from the
24-month BRIGHTER study (Group members of this study
are cited in Appendix 1, available at www.aaojournal.org).Methods
Study Design
The BRIGHTER study was a 24-month, phase IIIb, randomized,
open-label, active-controlled, 3-arm, multicenter study assessing
the efﬁcacy and safety proﬁle of an individualized stabilization
criteriaedriven PRN dosing regimen of ranibizumab 0.5 mg
with or without laser versus laser alone in patients with visual
impairment due to macular edema secondary to BRVO. The
study is being conducted across 17 countries worldwide
(Appendix 2, available at www.aaojournal.org). The study
started in May 2012 and was completed in 2015. The ﬁrst 6
months of the BRIGHTER study were conducted from May
2012 and November 2015 and included recruitment and all
the other steps.
The study was conducted in accordance with the Declaration of
Helsinki, and the study protocol was reviewed and approved by an
independent ethics committee or institutional review board at each
contributing center. Patients provided written informed consent
before entering the study. The study is registered with Clinical-
trials.gov as NCT01599650.Patients
The study population consisted of patients aged 18 years with
visual impairment due to macular edema secondary to BRVO. The
key inclusion criteria included a BCVA letter score at screening
and baseline between 73 and 19 Early Treatment Diabetic Reti-
nopathy Study (ETDRS) letters, inclusive (approximate Snellen
equivalent of 20/40 and 20/400).
The key exclusion criteria included stroke or myocardial
infarction <3 months before screening; uncontrolled blood pres-
sure (>160/>100 mmHg) at screening or baseline; periocular or
ocular infection or inﬂammation at screening or baseline; intra-
vitreal anti-VEGF injections 3 months before baseline and sys-
temic anti-VEGF injections 6 months before baseline;
uncontrolled glaucoma (intraocular pressure 30 mmHg on
medication or according to the investigator’s judgment) at the time
of screening or baseline or diagnosed within 6 months before
baseline; laser photocoagulation for macular edema 4 months
before baseline; intraocular or periocular corticosteroid use 3
months before baseline; and known hypersensitivity to ranibizu-
mab or any component of the ranibizumab formulation or ﬂuo-
rescein. In addition, pregnant or nursing women were excluded
from the study (inclusion and exclusion criteria are listed in
Appendix 3, available at www.aaojournal.org).
Randomization and Treatment
At enrollment, eligible patients were randomized in a 2:2:1 ratio to
receive ranibizumab 0.5 mg, ranibizumab 0.5 mg with laser, or
laser alone. The randomization list was generated using a validated
system that automates the random assignment of treatment arms to
randomization numbers in the speciﬁed ratio. The randomization
was balanced across the sites. Although this was an open-label
study, the vision examiner who assessed the BCVA outcomes
was masked and not allowed to perform any additional study tasks
that would have unmasked him or her to study treatment.
In the ranibizumab with or without laser groups, ranibizumab
0.5 mg was administered as recommended in the European Union
Summary of Product Characteristics (2012).7 Patients received
ranibizumab 0.5 mg injections on day 1, followed by initial
monthly injections until the study eye’s VA was stable (based on
the judgment of the investigator) for at least 3 consecutive
months; by design, at least 3 initial injections were required8
(Fig 1, available at www.aaojournal.org). Once VA was stable,
ranibizumab treatment was temporarily discontinued at the
investigator’s discretion. In the ranibizumab with laser and laser-
only groups, patients were treated with laser as soon as indicated
by the investigator. When ranibizumab and laser were to be
administered on the same day to the study eye, the laser
treatment was applied 30 minutes before the ranibizumab
injection.
Maintenance and Re-treatment
All patients were monitored monthly for VA and disease activity. If
there was a loss of VA due to disease activity as judged by the
investigator, monthly ranibizumab injections were again adminis-
tered to the patients in the ranibizumab with or without laser groups
until stability was achieved for 3 consecutive months; this required
at least 2 consecutive injections.8 In the ranibizumab with laser and
laser-only groups, patients were re-treated with laser at the in-
vestigator’s discretion at minimum intervals of 4 months in the
presence of macular edema secondary to BRVO, as long as the
BCVA was <79 letters.
In all 3 groups, the last possible treatment was administered at
month 5, and the last assessment was performed at month 6 for1333
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and baseline, the study eye was selected on the basis of the
investigator’s discretion. The other eye (labeled the fellow eye)
was allowed to receive ranibizumab treatment within the study
according to the local label, according to the investigator’s judg-
ment. The use of rescue medication was not permitted in this study.
Study Objectives
The primary objective of this 24-month study was to demonstrate
the superior efﬁcacy of ranibizumab with or without laser when
compared with laser alone over 6 months. This was assessed by
the mean change in BCVA from baseline at month 6 in patients
treated with ranibizumab with or without laser versus laser alone
(primary end point). The secondary objectives were (1) to compare
the efﬁcacy of ranibizumab with or without laser versus laser alone
for (a) the mean average change in BCVA from baseline to month
1 through month 6, (b) the proportion of patients with a BCVA
improvement of 10/15/30 letters at month 6, (c) the propor-
tion of patients attaining a BCVA of 73 letters at month 6, and (d)
the mean change in central reading center (CRC)eassessed central
subﬁeld thickness (CSFT) from baseline to month 6; (2) to assess
the treatment exposure of ranibizumab and laser; and (3) to eval-
uate the safety proﬁle of ranibizumab over 6 months. An explor-
atory objective was to evaluate the efﬁcacy of the 3 treatments in
relation to the following baseline characteristics: presence of
macular ischemia (present and absent); BCVA (39, 40e59, and
60 letters); and duration of BRVO (12 and >12 months), by
assessing the mean average change in BCVA from month 1
through month 6. An additional exploratory objective was to assess
the change from baseline to month 6 of the CRC-assessed categoric
optical coherence tomography (OCT) parameters (CSFT catego-
rized, CFT categorized, visible intraretinal cystoid ﬂuid [IRF], and
subretinal ﬂuid [SRF]). Deﬁnitions of these quantitative and cate-
goric spectral-domain OCT parameters are listed in Appendix 4
(available at www.aaojournal.org).
Efﬁcacy and Safety Assessments
Study assessments were performed at screening, baseline (day 1),
day 8, and monthly visits.
Best-Corrected Visual Acuity. The BCVA was assessed by
certiﬁed vision examiners at every study visit using ETDRS VA
testing charts at an initial testing distance of 4 m. If it was not
possible to perform a subjective refraction or VA testing at 4 m
because VA was too poor for the patient to read 4 letters on the
ETDRS chart at this distance, the refraction or VA testing were
attempted at 1 m.
Optical Coherence Tomography. Optical coherence tomogra-
phy was performed by certiﬁed site personnel at each visit using
spectral-domain OCT equipment (e.g., Heidelberg Spectralis
[Heidelberg Engineering, Heidelberg, Germany]; Cirrus HD-OCT
[Carl Zeiss, Oberkochen, Germany]; 3D-OCT 1000 or 3D-OCT
2000 [Topcon, Tokyo, Japan]; and Nidek RS-3000 [Nidek, Fre-
mont, CA]). The same equipment was used for assessment
throughout the study. The investigator or designated study staff
evaluated the images according to the standard practice and
recorded the required variables in the clinical database. The images
also were assessed by a CRC to ensure a standardized evaluation of
the CSFT (the average retinal thickness of the circular area with a
1-mm diameter around the foveal center) and to capture the pres-
ence or absence of qualitative parameters (i.e., CFT, IRF, and
SRF). Raw data of the images were evaluated in validated CRC
software. The inner and outer retinal boundaries were segmented at
predeﬁned standardized locations to ensure standardization across
the used spectral-domain OCT instruments.1334Fluorescein Angiography and Color Fundus Photo-
graphy. Fluorescein angiography (in conjunction with 7-ﬁeld color
fundus photography) images were evaluated by the investigator for
the presence or absence of macular edema, capillary leakage, and
nonperfusion within the 3-mm perifoveal subﬁeld.
The CRC used a standardized grading system to assess macular
ischemia on ﬂuorescein angiography, as reported previously.9
Macular ischemia was characterized by the extent of retinal
capillary loss (presence or absence of nonperfusion) in the
ETDRS-like grid center subﬁeld, as well as inner and outer sub-
ﬁelds (Appendix 5, available at www.aaojournal.org). We deﬁned
macular ischemia as present if capillary loss was scored as mild,
moderate, severe, or completely destroyed in 1 location of the
center, inner, or outer subﬁelds of the grid (Appendix 5, available
at www.aaojournal.org). In this article we present only the efﬁcacy
results based on CRC-assessed macular ischemia. The investigator
used all images to decide the need for re-treatment.
Treatment Exposure. Information on the number of ranibizu-
mab injections or laser administration over 6 months was collected.
Safety Assessments. Safety assessments included type, fre-
quency, and severity of adverse events (AEs) and serious AEs
(SAEs) over 6 months.
Statistical Analysis
By assuming a standard deviation (SD) of 14 letters for the change
(normal distributed) in BCVA from baseline at month 6, based on a
randomization ratio of 2:2:1 and estimating a dropout rate of
approximately 10%, a sample size of 180 randomized patients each
in the ranibizumab and ranibizumab þ laser arms and 90 patients in
the laser-only arm was considered. This sample size had a power
of 90.5% to detect a treatment difference of 7 or more letters at a
1-sided a level of 0.0125 for an unstratiﬁed analysis (based on
unstratiﬁed ManneWhitney test using PASS 2002 software;
NCSS, LLC, Kaysville, UT).
The primary and secondary efﬁcacy outcomes were analyzed
within the full analysis set (FAS) using the last observation carried
forward approach. The FAS included all randomized patients who
had 1 post-baseline assessment for BCVA in the study eye and
who received 1 administration of study treatment, except patients
randomized to laser monotherapy, who were included even without
receiving study treatment.
The hypothesis of the superiority of ranibizumab with
or without laser compared with laser alone was tested in parallel
according to the Hochberg procedure, controlling the overall 1-
sided a level at 0.025. The primary and secondary efﬁcacy out-
comes related to the mean change in BCVA from baseline were
assessed on the basis of pairwise analysis of variance models that
included factors for treatment and baseline BCVA category
(BCVA 39, 40e59, and 60 letters). The least squares means
and standard error were calculated for each of the treatment groups,
along with the 2 pairwise differences of their 95% conﬁdence in-
terval (CI). The number and proportion of patients with BCVA
letter gain or loss from baseline were analyzed by a stratiﬁed
CochraneManteleHaenszel test with stratiﬁcation based on base-
line BCVA (39, 40e59, 60 letters). The CRC-assessed CSFT
was summarized descriptively and analyzed via pairwise analysis
of variance models including factors for treatment, OCT machine
type, and categorized baseline BCVA (39, 40e59, and 60
letters). The CRC-assessed categoric OCT parameters were sum-
marized using FAS observed data for the study eye.
All safety analyses were descriptive and performed on the
safety set that included all patients who had 1 post-baseline
safety assessment and received 1 administration of the study
treatment, except for patients randomized to laser monotherapy,
who were included even without receiving the study treatment.
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(SAS Institute, Inc., Cary, NC).Results
Patient Disposition
A total of 455 patients were randomized to receive ranibizumab
(183 patients), ranibizumab with laser (180 patients), or laser
alone (92 patients) (Fig 2). A total of 424 patients (93.2%)
completed the ﬁrst 6 months of the study (174 in the
ranibizumab group, 170 in the ranibizumab with laser group, and
80 in the laser-only group) (Fig 2). Overall, withdrawal of
consent (n ¼ 12) and AEs (n ¼ 8) were the most common
reasons for study discontinuation. The FAS included 180 patients
receiving ranibizumab, 178 patients receiving ranibizumab with
laser, and 90 patients receiving laser monotherapy. The safety
analysis set included 180 patients receiving ranibizumab, 183
patients receiving ranibizumab with laser (there were 3 patients
in the laser monotherapy group who received ranibizumab and 1
patient in the ranibizumab monotherapy group who received
laser treatment, resulting in percentages >100%), and 88 patients
receiving laser monotherapy.
The baseline demographic characteristics were comparable
among the 3 treatment groups (Table 1). Overall, the mean (SD)
age of the patients was 66.3 (10.30) years, the proportion of
male and female patients was similar (49.7% vs. 50.3%), and the
majority (94.9%) of patients were white (Table 1). The baseline
mean (SD) BCVA was 57.7 (12.88) letters, and the majority of
patients (52.5%) had a BCVA letter score 60 at baseline
(Table 1). The mean (SD) duration of BRVO was 9.9 (21.28)
months, and the median duration was 2.9 months (Table 1). The
BRVO subtype was BRVO in 89.0% of patients and hemi-retinalFigure 2. Patient disposition (randomized set). Randomized set consisted of all
counted once for each reason of nonrandomization, percentages may add up
occlusion.vein occlusion in 10.5% of patients (Table 1). Overall, 24.8% of
patients in the randomized set had ischemic perfusion type at
baseline, according to the investigator’s assessment. The
proportion of patients with macular ischemia at baseline based
on CRC assessment was similar between treatment groups
(48.1% of patients in the ranibizumab group, 40.0% of patients
in the ranibizumab with laser group, and 44.6% of patients in the
laser only group). There were 31.1%, 37.8%, and 31.5% of
patients with macular ischemia as “cannot grade” based on CRC
assessment in the ranibizumab, ranibizumab with laser, and laser-
only groups, respectively.
Efﬁcacy
Best-Corrected Visual Acuity. Ranibizumab with or without laser
was superior to laser alone in improving mean (SD) BCVA from
baseline at month 6 (14.8 [10.70] and 14.8 [11.13] vs. 6.0 [14.27]
letters, respectively; both P < 0.0001); thus, the primary end point
was met (Fig 3). Likewise, mean (SD) average gain in BCVA from
month 1 through month 6 was higher in the ranibizumab (13.2
[9.60] letters) and ranibizumab with laser groups (13.2 [9.89]
letters) compared with the laser-only group (4.8 [11.69] letters);
estimated least square means (standard error; 95% CI) treatment
difference versus laser were 9.4 letters [1.21; 7.0e11.7] (P <
0.0001) for ranibizumab and 8.2 letters [1.24; 5.8e10.6] (P <
0.0001) for ranibizumab with laser. In the ranibizumab and
ranibizumab with laser groups, a rapid and clinically relevant
improvement in mean BCVA was observed at month 1, which
continued up to month 3 and slightly increased from month 3
until the last assessment time point at month 6 (Fig 3).
At month 6, a larger proportion of patients gained10/15/30
letters with ranibizumab with or without laser versus laser alone
(Fig 4). At month 6, 65.6% and 54.5% of patients attained a BCVA
score of 73 letters with ranibizumab and ranibizumab with laser,patients who were randomized. Because patients with multiple reasons are
to more than 100%. AE ¼ adverse event; BRVO ¼ branch retinal vein
1335
Table 1. Baseline Demographics, Disease, and Ocular Characteristics (Randomized Set*)
Demographic Variable Ranibizumab 0.5 mg (n [ 183)
Ranibizumab 0.5 mg D laser
(n [ 180) Laser monotherapy (n [ 92) Total (N [ 455)
Age, yrs
n 183 180 92 455
Mean (SD) 64.7 (10.34) 67.3 (10.41) 67.7 (9.67) 66.3 (10.30)
Sex, n (%)
Male 93 (50.8) 96 (53.3) 37 (40.2) 226 (49.7)
Female 90 (49.2) 84 (46.7) 55 (59.8) 229 (50.3)
Predominant race, n (%)
White 171 (93.4) 172 (95.6) 89 (96.7) 432 (94.9)
Black 1 (0.5) 1 (0.6) 0 2 (0.4)
Asian 5 (2.7) 3 (1.7) 3 (3.3) 11 (2.4)
Native American 1 (0.5) 0 0 1 (0.2)
Other 5 (2.7) 4 (2.2) 0 9 (2.0)
VA (letters)
n 181 179 91 451
Mean (SD) 59.5 (11.77) 56.6 (13.16) 56.5 (14.13) 57.7 (12.88)
VA stratiﬁcation group,
n (%)
39 letters 16 (8.7) 22 (12.2) 11 (12.0) 49 (10.8)
40e59 letters 55 (30.1) 72 (40.0) 36 (39.1) 163 (35.8)
60 letters 110 (60.1) 85 (47.2) 44 (47.8) 239 (52.5)
Missing 2 (1.1) 1 (0.6) 1 (1.1) 4 (0.9)
IOP, mmHg
n 181 179 91 451
Mean (SD) 15.1 (2.49) 15.4 (3.02) 15.2 (2.88) 15.2 (2.79)
Subtype of BRVO, n (%)
Hemi 19 (10.4) 19 (10.6) 10 (10.9) 48 (10.5)
Branch 164 (89.6) 159 (88.3) 82 (89.1) 405 (89.0)
Missing 0 2 (1.1) 0 2 (0.4)
Perfusion type,y n (%)
Ischemic 47 (25.7) 42 (23.3) 24 (26.1) 113 (24.8)
Nonischemic 135 (73.8) 134 (74.4) 66 (71.7) 336 (73.8)
Missing 1 (0.5) 4 (2.2) 1 (1.1) 6 (1.3)
Duration of BRVO, months
n 181 179 90 450
Mean (SD) 10.3 (19.63) 9.2 (19.92) 10.5 (26.66) 9.9 (21.28)
Median 3.1 3.3 2.0 2.9
Duration of BRVO, n (%)
12 mos 145 (79.2) 145 (80.6) 76 (82.6) 366 (80.4)
>12 mos 36 (19.7) 34 (18.9) 14 (15.2) 84 (18.5)
Missing 2 (1.1) 1 (0.6) 2 (2.2) 5 (1.1)
BRVO ¼ branch retinal vein occlusion; IOP ¼ intraocular pressure; SD ¼ standard deviation; VA ¼ visual acuity.
Percentages are based on the total number of patients in the randomized set.
Baseline was deﬁned as the last available nonmissing value collected just before the start of treatment.
*Consisted of all patients who were randomized.
yPerfusion type as indicated by the investigator.
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(estimated treatment difference vs. laser, 34.44% [95% CI,
22.6e46.3] for ranibizumab and 23.38% [95% CI, 11.3e35.4] for
ranibizumab with laser; both P < 0.0001).
Mean gains in BCVA from baseline to month 6 in the ranibi-
zumab with or without laser groups were similar between patients
with or without macular ischemia (CRC assessed) at baseline. Mean
(SD) change in BCVA from baseline to month 6 in patients with
macular ischemia was 14.3 (10.52) letters in the ranibizumab group,
14.4 (8.72) letters in the ranibizumab with laser group, and 9.2
(11.65) letters in the laser-only group (Fig 5). Mean (SD) change in
BCVA from baseline at month 6 in patients without macular
ischemia was 11.9 (10.06) letters in the ranibizumab group, 11.8
(8.66) letters in the ranibizumab with laser group, and 2.7 (17.22)
letters in the laser-only group (Fig 5).1336Mean gain in BCVA at month 6 by baseline VA subgroups
(39/40e59/60 letters) was 20.9/19.5/11.6 letters in the ranibi-
zumab group, 19.5/17.9/11.1 letters in the ranibizumab with laser
group, and 18.7/11.4/1.4 letters in the laser-only group (Fig 6). In
both the ranibizumab and ranibizumab with laser groups, patients
with a poor baseline VA had a better mean BCVA gain at month
6 than those with a higher baseline VA, although the absolute
ﬁnal BCVA values were lower in those with poor baseline VA
(Fig 6).
Mean gain in BCVA by prior duration of BRVO (12/>12
months) was 16.4/8.4 letters in the ranibizumab group, 15.0/11.5
letters in the ranibizumab with laser group, and 5.9/7.1 letters in the
laser-only group (Fig 7).
Anatomic Outcomes. At month 6, there was a greater reduc-
tion in CRC-assessed mean CSFT in patients treated with
Figure 3. Mean change in best-corrected visual acuity (BCVA) from baseline to month 6 (full analysis set [FAS]). The FAS consisted of all randomized
patients who had 1 postbaseline assessment for BCVA in the study eye and who received1 administration of study treatment, except patients randomized
to laser monotherapy, who were included even without receiving study treatment. yBoth ranibizumab and ranibizumab þ laser versus laser alone, pairwise
analysis of variance. SE ¼ standard error.
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with laser alone (223.3/240.1 vs. 89.8 mm; P < 0.0001) (Fig 8).
At month 6, the proportion of patients with CSFT and CFT 450
mm increased from baseline in all treatment groups; the proportion
was higher in the ranibizumab with or without laser groups
than in the laser-only group (Table 2A, available at
www.aaojournal.org). The proportion of patients with visible
IRF and SRF decreased from baseline in all treatment groups;
the proportion was higher in the ranibizumab with or without
laser groups than in the laser-only group (Table 2B, available at
www.aaojournal.org).Figure 4. Categorized gain in best-corrected visual acuity (BCVA) at
month 6 (full analysis set [FAS]). The FAS consisted of all randomized
patients who had 1 post-baseline assessment for BCVA in the study eye
and who received 1 administration of study treatment, except patients
randomized to laser monotherapy, who were included even without
receiving study treatment.Treatment Exposure
Ranibizumab Injections. The mean number of ranibizumab in-
jections over 6 months was 4.8 and 4.5 in the ranibizumab and
ranibizumab with laser groups, respectively (Fig 9).
Laser Treatments. The mean number of laser treatments given
up to 6 months was 0.0, 0.8, and 1.2 in the ranibizumab, ranibi-
zumab with laser, and laser-only groups, respectively (Fig 10).Safety
Serious Adverse Events. Ocular SAEs were reported in the study
eye in 2 patients in the ranibizumab with laser group during the
6 months of the study: macular hole in 1 patient (not considered by
the investigator to be related to the study drug or ocular injection)
and ocular ischemic syndrome (considered by the investigator to
be related to the study drug) in the other patient (Table 3,
available at www.aaojournal.org). Nonocular SAEs were reported
in 10, 7, and 2 patients in the ranibizumab, ranibizumab with
laser, and laser-only groups, respectively (Table 3, available at
www.aaojournal.org). One patient died of acute respiratory
failure in the ranibizumab group (Table 3, available at
www.aaojournal.org). The death was not considered by the
investigator to be related to the study treatment or ocular injection.
Adverse Events. Ocular AEs in the study eye were reported in
28.3%, 37.2%, and 13.6% of patients in the ranibizumab, ranibi-
zumab with laser, and laser-only groups, respectively (Table 4).
Conjunctival hemorrhage and eye pain were the most commonly
reported ocular AEs in patients receiving ranibizumab or
ranibizumab with laser (Table 4).
The incidence of nonocular AEs was similar among the 3
groups (Table 4). Hypertension was the most common nonocular
AE reported in all 3 groups. Ocular and nonocular AEs1337
Figure 5. Mean change in best-corrected visual acuity (BCVA) from baseline to month 6 by baseline macular ischemia (full analysis set [FAS]). The FAS
consisted of all randomized patients who had 1 postbaseline assessment for BCVA in the study eye and who received 1 administration of study treatment,
except patients randomized to laser monotherapy, who were included even without receiving study treatment. D ¼ day.
Ophthalmology Volume 123, Number 6, June 2016suspected to be related to the study drug treatment during the ﬁrst 6
months of the study are listed in Table 5 (available at
www.aaojournal.org). Treatment- or ocular injectionerelated
ocular AEs were reported in 17.8% of patients in the ranibizu-
mab group and 23.5% of patients in the ranibizumab with laser
group. Nonocular AEs occurred in 1.7% of patients in the ranibi-
zumab group, 2.2% of patients in the ranibizumab with laser group,
and none in the laser-only group. Ocular and nonocular AEs
leading to study drug discontinuation are listed in Table 6
(available at www.aaojournal.org).
There were no reports of retinal neovascularization during the
6-month period of this study. Retinal hemorrhages were
reported in <2% of patients treated with ranibizumab (ranibizu-
mab, 0.6%; ranibizumab with laser, 1.1%) and in 3.4% of patients
treated with laser alone. Vitreous hemorrhages were reported in
0.6% of patients in the ranibizumab group, 1.1% of patients in the
ranibizumab with laser group, and none in the laser-only group.
There were no cases of neovascular glaucoma or iris neo-
vascularization during the ﬁrst 6-month period of the 24-month
BRIGHTER study.Discussion
The BRIGHTER study evaluated the individualized stabi-
lization criteriaedriven PRN dosing regimen of1338ranibizumab 0.5 mg, mainly based on VA stabilization
criteria, with or without laser versus laser alone in patients
with visual impairment due to macular edema secondary to
BRVO and with a longer disease duration. Laser treatment,
the active comparator in this study, has previously been
shown to stabilize VA in patients with BRVO, but im-
provements in VA are suggested to be delayed and of lower
amplitude.10,11 In addition, in patients with diabetic reti-
nopathy, the structural damage due to repeated treatment
with laser alone has been shown to worsen over time
because of an enlargement of coagulation scars.12 Thus, this
study assessed the combination of ranibizumab with laser to
evaluate the potential synergistic beneﬁts. The effect of laser
treatment used in combination with ranibizumab may,
theoretically, result in better maintenance of the VA gains
obtained with ranibizumab, which may reduce the need
for re-treatment with ranibizumab or the number of
follow-up visits.
In this study, the individualized VA stabilization
criteriaedriven PRN treatment with ranibizumab 0.5 mg
with or without laser resulted in a signiﬁcant improvement
in BCVA at month 6 compared with laser alone. This dosing
regimen of ranibizumab is as recommended in the European
Union,7 and the study results further validate this
Figure 6. Mean change in best-corrected visual acuity (BCVA) from baseline to month 6 by baseline BCVA (full analysis set [FAS]). FAS consisted of all
randomized patients who had1 postbaseline assessment for BCVA in the study eye and who received 1 administration of study treatment, except patients
randomized to laser monotherapy, who were included even without receiving study treatment. D ¼ day.
Tadayoni et al  Ranibizumab versus Laser in BRVOrecommended dosing regimen. The 6-month primary anal-
ysis did not show additional beneﬁts with the ranibizumab
plus laser combination over ranibizumab monotherapy,
either in BCVA outcomes or in the required number of in-
jections, which could be due to the short duration assess-
ment of this 24-month study.
The patients in this study required a mean of 4.8 rani-
bizumab 0.5 mg injections (of which 3 were mandatory per
protocol) over 6 months to achieve mean BCVA gains
of þ14.8 letters. In real-life studies with ranibizumab in
patients with neovascular age-related macular degeneration
or central retinal vein occlusion, the mean number of in-
jections over a 1-year period have been reported to range
between 4 and 5 in the retrospective analysis part of the
LUMINOUS study and 4.4 in the VERO study.13,14
At month 6, the proportion of patients with a gain of
15 letters in the BRAVO study with monthly ranibizu-
mab treatment was higher than in the BRIGHTER studywith stabilization criteriaedriven PRN ranibizumab treat-
ment (61.1% vs. 45.0%). The mean change in BCVA from
baseline at month 6 was numerically higher in the BRAVO
study (þ18.3 letters) compared with the BRIGHTER study
(þ14.8 letters),4 which could be due to the differences in
patient baseline characteristics in the 2 studies. Patients in
the BRIGHTER study had a higher mean baseline BCVA
score (59.5 letters in BRIGHTER vs. 53.0 letters in
BRAVO) and a longer mean duration of BRVO (9.9
months in BRIGHTER vs. 3.3 months in BRAVO).
However, the absolute mean BCVA at month 6 was
higher in the BRIGHTER study than in the BRAVO study
(74.3 vs. 71.3 letters) (Fig 11), with a lower mean number
of injections (4.8 vs. 5.7, respectively). The functional
outcomes observed at month 6 of the BRIGHTER study
were similar to those of the VIBRANT study (assessing
aﬂibercept for the treatment of BRVO15), in which 52.7%
of patients gained 15 letters and mean BCVA change1339
Figure 7. Mean change in best-corrected visual acuity (BCVA) from baseline to month 6 by duration of branch retinal vein occlusion (full analysis set
[FAS]). The FAS consisted of all randomized patients who had 1 postbaseline assessment for BCVA in the study eye and who received 1 administration
of study treatment, except patients randomized to laser monotherapy, who were included even without receiving study treatment. D ¼ day; M ¼ month.
Ophthalmology Volume 123, Number 6, June 2016from baseline was 17.0 letters, and provide further support
to the ﬁndings of VIBRANT that suppression of VEGF
over 6 months provides superior visual outcomes
compared with treatment with focal/grid laser alone.
However, any comparisons between BRIGHTER and
previous studies of patients with BRVO need to be
interpreted with caution considering the differences in the
patient populations, study designs, and anti-VEGF treat-
ment regimens investigated.
The exploratory subgroup analysis performed in the
BRIGHTER study showed that the individualized stabi-
lization criteriaedriven PRN dosing regimen of ranibi-
zumab was effective in patients with BRVO irrespective
of the baseline VA, disease duration, or presence of
macular ischemia. The mean change in BCVA from
baseline at month 6 with ranibizumab treatment was
similar between patients with ischemia and patients
without ischemia. The difference in the percentage of
patients at baseline with CRC-assessed macular ischemia
and investigator-assessed nonperfusion could be related
to the individual assessment method used and needs to be
investigated in future studies. In addition, the impact of1340the severity and location of ischemia on efﬁcacy warrants
further investigation.
Several studies of anti-VEGF for other indications have
shown baseline VA to be an important predictor of VA
outcomes at later time points.16e19 Likewise, in
BRIGHTER, the mean gain in BCVA at month 6 was
higher in patients with lower baseline VA scores, whereas
the absolute ﬁnal BCVA values were lower in those with
poor baseline VA. In addition, BCVA gain at month 6 was
higher in patients with a shorter duration of disease, sug-
gesting that early treatment initiation with ranibizumab
irrespective of the BCVA scores may provide better VA
gains in patients with BRVO. This is supported by the
reduced visual gains observed in the sham arm of the
BRAVO study due to delayed treatment initiation
(switching into PRN treatment after 6 months).
Similar ﬁndings have been reported in the sham arms of
studies of ranibizumab for other indications,20 as well as in
observational studies of patients with age-related macular
degeneration.21,22
No new safety concerns were identiﬁed with ranibizumab
with or without laser treatment. The single death reported in
Figure 8. Mean change in central subﬁeld foveal thickness (CSFT) from baseline to month 6 (full analysis set [FAS]). The FAS consisted of all randomized
patients who had 1 postbaseline assessment for BCVA in the study eye and who received1 administration of study treatment, except patients randomized
to laser monotherapy, who were included even without receiving study treatment. yBoth ranibizumab and ranibizumab þ laser versus laser alone, pairwise
analysis of variance. SE ¼ standard error.
Tadayoni et al  Ranibizumab versus Laser in BRVOthe ranibizumab group was not related to the study drug.
There were no reports of endophthalmitis, neovascular
glaucoma, or iris neovascularization.
This is a 6-month primary analysis of a study. This short
period was insufﬁcient to provide conclusive evidence of theFigure 9. Ranibizumab treatment exposure up to month 6 (safety set). Safety s
received 1 administration of study treatment, except patients randomized
treatment. The total number of injections per patient is calculated, and these pbeneﬁts of combining laser with ranibizumab, especially
because laser administration occurred at aminimum interval of
4months. The exploratory analysis of the effect of ranibizumab
treatment focused on macular ischemia. This study explicitlyet consisted of all patients who had 1 postbaseline safety assessment and
to laser monotherapy, who were included even without receiving study
er-patient values are summarized. SD ¼ standard deviation.
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Figure 10. Laser treatment exposure up to month 3 (safety set). Safety set consisted of all patients who had 1 postbaseline safety assessment and received
1 administration of study treatment, except patients randomized to laser monotherapy, who were included even without receiving study treatment.
Multiple sessions for the initial laser treatment are counted as 1 application. The total number of laser applications per patient is calculated, and these per-
patient values are summarized. SD ¼ standard deviation.
Ophthalmology Volume 123, Number 6, June 2016excluded patients with previous treatments within 3
months like other randomized studies to facilitate comparison.Table 4. Ocular (Study Eye) and Nonocular Adverse Events
Regardless of Study Drug Relationship (Safety Set*)
Preferred Term
n (%)
Ranibizumab
0.5 mg
(n [ 180)
Ranibizumab
0.5 mg D Laser
(n [ 183)
Laser
Monotherapy
(n [ 88)
Ocular AEs,
total
51 (28.3) 68 (37.2) 12 (13.6)
Conjunctival
hemorrhage
11 (6.1) 12 (6.6) 0 (0)
Eye pain 8 (4.4) 10 (5.5) 0 (0)
Vitreous
detachment
6 (3.3) 4 (2.2) 0 (0)
IOP increased 5 (2.8) 8 (4.4) 0 (0)
Vitreous ﬂoaters 3 (1.7) 5 (2.7) 2 (2.3)
Nonocular AEs,
total
60 (33.3) 52 (28.4) 27 (30.7)
Hypertension 11 (6.1) 10 (5.5) 5 (5.7)
Nasopharyngitis 6 (3.3) 5 (2.7) 3 (3.4)
Headache 4 (2.2) 6 (3.3) 3 (3.4)
AE ¼ adverse event; IOP ¼ intraocular pressure.
Preferred terms that occurred in 2% of the safety set are included in this
summary. Preferred terms are sorted in descending frequency, as reported in
the ranibizumab 0.5 mg column. A patient with multiple occurrences of an
AE under 1 treatment is counted only once in the AE category for that
treatment.
*Consisted of all patients who had 1 postbaseline safety assessment and
received1 administration of study treatment, except patients randomized to
laser monotherapy, who were included even without receiving study
treatment.
1342The 24-month results of the BRIGHTER study are ex-
pected to provide additional information on the long-term
efﬁcacy and safety of the individualized stabilization
criteriaedriven dosing of ranibizumab 0.5 mg, as well as the
long-term beneﬁts of combining ranibizumab with laser.
The individualized stabilization criteriaedriven dosing
regimen used in this study led to an average reduction of 1
injection over the course of 6 months in comparison with
monthly dosing. The second-year data from this study will
provide further information on the beneﬁts of fewer visits
combined with the individualized dosing regimen.
In conclusion, the 6-month data from the BRIGHTER
study demonstrate that an individualized ranibizumab
treatment with or without laser is superior to laser mono-
therapy in signiﬁcantly improving BCVA in patients with
BRVO. The exploratory analysis showed similar BCVAFigure 11. Mean best-corrected visual acuity (BCVA) from baseline to
month 6 in BRIGHTER and BRAVO. yBCVA was assessed on day 7 in
BRAVO and day 8 in BRIGHTER. D ¼ day.
Tadayoni et al  Ranibizumab versus Laser in BRVOgains between patients with macular ischemia and patients
without macular ischemia, and suggests that better VA gains
may be obtained at 6 months with early treatment initiation
irrespective of the baseline BCVA scores. Overall, there
were no safety concerns other than those reported in the
previous studies.
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